The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.
Site Search
The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.
The European Commission has approved the cystic fibrosis drug Orkambi® for people with two copies of the F508del mutation ages 12 and older in the European Union.
Today, more than 4,000 cystic fibrosis research scientists, clinicians and caregivers are gathering in Phoenix for the 29th Annual North American Cystic Fibrosis Conference (NACFC) in the largest collaborative forum of its kind.
NCQA Honors The Foundation for Leadership in Improving Care
HealthWell to offer co-pay assistance for CF-specific, FDA-approved drugs including prescribed vitamins and supplements.
To the CF Foundation Staff and CF Community: Today, after 35 years with the Cystic Fibrosis Foundation -- and 21 years as president and CEO -- Robert J. Beall, Ph.D., has announced he is stepping down.
Robert J. Beall, Ph.D., today announced he will step down as president and chief executive officer of the Cystic Fibrosis Foundation, effective December 31, 2015. Preston W. Campbell III, M.D., currently the Foundation's executive vice president for medical affairs, will succeed Dr. Beall as president and CEO.
The Cystic Fibrosis Foundation's drug development model, mission and leadership are featured on the front page of The Washington Post today.